News | November 29, 2022
Fredun Pharmaceuticals signs two large contracts
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
He brings over 30 years of experience across various organizations such as Asian Paints PPG, Berger Paints, Tata Steel, among others
The product is expected to be launched by Q4 FY23.
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company sees the business reaching $100mn
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
Subscribe To Our Newsletter & Stay Updated
